Clin2
NCT07441395Possibly a fitRecruiting

Study of soquelitinib for moderate to severe eczema

Atopic DermatitisAtopic Dermatitis EczemaEczemaEczema, Atopic

Treatments studied

Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.

This trial tests an experimental pill called soquelitinib for people with moderate to severe eczema (atopic dermatitis). It aims to see if the drug can reduce symptoms like itching and skin inflammation.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
200 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have had eczema for at least one year.
  • Your eczema is moderate to severe, covering at least 10% of your body and with significant itching.
  • You have tried topical creams or systemic treatments for eczema in the past 6 months.
  • If you are a woman able to have children, you agree to use effective birth control and are not pregnant or breastfeeding.
  • You do not have other active skin conditions or infections that could interfere with the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07216027Recruiting· Phase 2
A study of a new eczema medicine for adults

This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.

Huntington Beach, California
NCT06807268Recruiting· Phase 3
A study of abrocitinib for children ages 6–11 with eczema

This trial tests a daily pill called Abrocitinib to see if it can help children ages 6 to 11 with moderate-to-severe eczema that hasn't gotten better with creams or ointments. Eczema (also called atopic dermatitis) causes itchy, red skin, and this medicine might calm the immune response to reduce itching and rashes.

Birmingham, Alabama
NCT06880276Recruiting· Phase 3
Studying QLM3003 ointment for mild or moderate eczema

This trial tests if an ointment called QLM3003 is safe and helps adults with mild to moderate atopic dermatitis (eczema). It may be a new treatment option for people whose eczema affects small areas of skin.

Shenyang
NCT05995964Recruiting· Phase 2
Study of two new medicines for eczema

This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.

Birmingham, Alabama
NCT07488065Recruiting· Phase 1
New drug for moderate to severe eczema

This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.

Shanghai
NCT06775860Recruiting· Phase 3
Testing ICP-332 for moderate to severe eczema

This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.

Hefei, Anhui

Hear when a new Atopic Dermatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.